---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-025203"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2023-09-05T23:59:59+00:00"
generated_at: "2026-06-10T23:51:42.211645+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CMO Kirsten Gruis resigns; interim CMO Jordan Dubow appointed for stroke trial

## Summary
- CMO Kirsten Gruis resigned effective Aug 31, 2023; she will consult for 9 months at $33,500/month.
- Jordan Dubow, M.D., vascular neurologist with extensive CMO experience, engaged as interim CMO.
- Dr. Dubow to accelerate site engagement and enrollment in Phase 2/3 ReMEDy2 trial of DM199 for acute ischemic stroke.
- Dr. Dubow has served as CMO for eight companies and worked on 16 NDAs through FDA's Division of Neurology.
- Separation agreement includes standard non-disparagement and confidentiality; no severance as resignation was voluntary.

## SEC filing metadata
- accession: 0001437749-23-025203
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2023-09-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774923025203/0001437749-23-025203-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774923025203/dmtp20230903_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-025203
- JSON: https://secwatch.observer/filing/0001437749-23-025203.json
- Plain text: https://secwatch.observer/filing/0001437749-23-025203.txt

## Key facts
- Executive change
  Kirsten Gruis resigned as Chief Medical Officer at DiaMedica Therapeutics Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On September 3, 2023, Kirsten Gruis, M.D. resigned from her position as Chief Medical Officer of DiaMedica Therapeutics Inc. (“DiaMedica” or the “Company”), effective as of August 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401040/000143774923025203/0001437749-23-025203-index.htm
- Executive change
  Jordan Dubow was appointed as Chief Medical Officer at DiaMedica Therapeutics Inc..
  - Action: engaged
  - Role: Chief Medical Officer
  source text: To replace Dr. Gruis immediately on an interim basis while DiaMedica completes its search for a permanent Chief Medical Officer, DiaMedica has engaged as an independent consultant, Jordan Dubow, M.D.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401040/000143774923025203/0001437749-23-025203-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.